New Delhi, May 9 -- Indian pharma stocks are attracting foreign institutional investors (FIIs) due to their strong export orientation, especially in regulated markets like the US, and consistent demand for generics and speciality drugs.

Companies are benefiting from cost advantages, improving compliance records, and a growing focus on complex formulations and APIs.

Additionally, defensive characteristics during global uncertainty make pharma appealing. Here are three pharma stocks where FIIs have hiked their stake in the March 2026 quarter.

Shilpa Medicare is a niche Indian pharma company focused on oncology APIs, complex formulations, and CDMO services. It is transitioning toward higher-margin segments, such as biologics and specialit...